D-0623-2025 Class II Ongoing
FDA drug recall D-0623-2025 was initiated by Zydus Pharmaceuticals (USA) Inc on Aug 27, 2025 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity. The recall status is ongoing. Affected quantity: 270,125 Vials.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 17, 2025
- Initiation Date
- Aug 27, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 270,125 Vials
Product description
Succinylcholine Chloride Injection, USP 200 mg/10 mL (20 mg/mL), Rx only, 10 mL Multiple-dose Vial, Sterile, Manufactured by Zydus Lifesciences Ltd, Vadodara, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1377-1 (vial), NDC 70710-1377-2 (carton).
Reason for recall
Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.
Distribution pattern
MS, OH, LA, and Puerto Rico
Code information
Lot #s: L400077, exp: 8/31/2025; L400113, exp.: 9/30/2025; L400372, L400373, exp.: 3/31/2026; L400374, exp.: 4/30/2026.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0623-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026